FT839 cell therapy for autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a moderate or severe autoimmune disease (such as lupus, rheumatoid arthritis, or vasculitis) that has not responded to at least two prior treatments.
- Your major organs (heart, lungs, liver, kidneys) must be functioning reasonably well to handle the treatment.
- You cannot be pregnant, nursing, or have a history of certain infections, cancers, or organ transplants.
- You must not have received anti-CD19 or anti-CD20 therapies within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new treatment using your own immune cells, modified in a lab to attack harmful cells causing your autoimmune disease. It is for people with severe rheumatoid arthritis, lupus, Sjogren's syndrome, scleroderma, or myositis who have not improved with other treatments.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hear when a new Idiopathic Inflammatory Myositis (IIM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.